Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Accu-Break Pharmaceuticals or ABP and Midas Pharma have signed a cooperation agreement, pursuant to which, both the parties will work together to license the Accu-Break Technologies to European brand and generic pharmaceutical companies and to develop and market ABP products in Europe.
Subscribe to our email newsletter
Midas will assist ABP in the introduction, marketing and promotion of the Accu-Break Technologies to potential collaboration partners. Additionally, Midas may assist ABP in the preparation of regulatory information and in communications with health authorities and European opinion leaders to promote the licensing of the Accu-Break Technologies.
Allan Kaplan, ABP’s CEO, said: “This agreement with Midas will help broaden the opportunities available to ABP to license the patented and patent pending Accu-Break Technologies worldwide.”